CAL-101

TargetMol
Product Code: TAR-T8651
Supplier: TargetMol
CodeSizePrice
TAR-T8651-5mg5mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8651-10mg10mg£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8651-1mL1 mL * 10 mM (in DMSO)£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8651-25mg25mg£127.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8651-50mg50mg£142.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8651-100mg100mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8651-200mg200mg£226.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
CAL-101 is a selective inhibitor of p110δ(IC50 : 2.5 nM; in cell-free assays); shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
CAS:
1146702-54-6
Formula:
C22H18FN7O
Molecular Weight:
415.42
Pathway:
PI3K/Akt/mTOR signaling
Purity:
0.9939
SMILES:
O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)C)=NC5=C1C(F)=CC=C5
Target:
PI3K

References

Zhang X, Dai Q, Shan J, et al.Inhibition of phosphoinositide?3 kinases ?/? ameliorates pulmonary granuloma by rescuing Treg function in a sarcoidosis model.Experimental and Therapeutic Medicine.2023, 25(5): 1-11. Sarah E M Herman , Amber L Gordon, Amy J Wagner,et al.Phosphatidylinositol 3-kinase-? inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.Blood. 2010 Sep 23;116(12):2078-88. Brian J Lannutti, Sarah A Meadows, Sarah E M Herman,et al.CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.Blood. 2011 Jan 13;117(2):591-4.